TrialInvestigational new drugs2020

First-in-human, phase I single-ascending-dose study of the safety, pharmacokinetics, and relative bioavailability of selatinib, a dual EGFR-ErbB2 inhibitor in healthy subjects.

Meng-Na Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.